MCID: AMY004
MIFTS: 65

Amyloidosis malady

Categories: Metabolic diseases, Genetic diseases, Rare diseases, Neuronal diseases, Bone diseases, Cardiovascular diseases, Nephrological diseases, Immune diseases, Blood diseases

Aliases & Classifications for Amyloidosis

Summaries for Amyloidosis

MedlinePlus : 41 amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. the deposits can collect in organs such as the kidney and heart. this can cause the organs to become stiff and unable to work the way they should. there are three main types of amyloidosis: primary - with no known cause secondary - caused by another disease, including some types of cancer familial - passed down through genes symptoms can vary, depending upon which organs are affected. treatment depends on the type of amyloidosis you have. the goal is to help with symptoms and limit the production of proteins. if another disease is the cause, it needs to be treated.

MalaCards based summary : Amyloidosis, also known as amyloid disease, is related to cellulitis and charcot-marie-tooth disease, and has symptoms including hemiparesis, facial palsy and inguinal hernia. An important gene associated with Amyloidosis is TTR (Transthyretin), and among its related pathways/superpathways are Innate Immune System and Metabolism of proteins. The drugs Zinc and Pramlintide have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and kidney, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 An acquired metabolic disease that involves abnormal deposited of amyloid proteins in organs and/or tissues.

Wikipedia : 71 Amyloidosis is a group of diseases in which abnormal protein, known as amyloid fibrils, builds up in... more...

Related Diseases for Amyloidosis

Diseases in the Amyloidosis family:

Amyloidosis, Hereditary, Transthyretin-Related Al Amyloidosis
Amyloidosis Aa Hereditary Amyloidosis
Primary Localized Amyloidosis Ah Amyloidosis

Diseases related to Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)
id Related Disease Score Top Affiliating Genes
1 cellulitis 29.3 GSN OSMR SAA1 TTR
2 charcot-marie-tooth disease 29.1 APP CST3 PRNP
3 amyloidosis, hereditary, transthyretin-related 12.4
4 al amyloidosis 12.4
5 primary cutaneous amyloidosis 12.4
6 amyloidosis, familial visceral 12.4
7 amyloidosis, finnish type 12.3
8 hereditary amyloidosis 12.3
9 amyloidosis aa 12.3
10 amyloidosis, primary localized cutaneous, 1 12.2
11 familial amyloidosis, finnish type 12.1
12 amyloidosis, primary localized cutaneous, 2 12.1
13 wild type attr amyloidosis 12.0
14 aapoaii amyloidosis 12.0
15 multiple myeloma 11.9
16 primary localized amyloidosis 11.9
17 cerebral amyloid angiopathy 11.9
18 ah amyloidosis 11.9
19 alect2 amyloidosis 11.9
20 muckle-wells syndrome 11.9
21 wild type abeta2m amyloidosis 11.9
22 aapoai amyloidosis 11.9
23 afib amyloidosis 11.8
24 macular amyloidosis 11.8
25 lichen amyloidosis 11.8
26 nodular cutaneous amyloidosis 11.8
27 variant abeta2m amyloidosis 11.8
28 aapoaiv amyloidosis 11.8
29 leptomeningeal amyloidosis 11.8
30 amyloidosis cutis dyschromia 11.8
31 cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants 11.7
32 amyloidosis beta2m 11.7
33 familial oculoleptomeningeal amyloidosis 11.7
34 amyloidosis nodular localized cutaneous 11.7
35 amyloidosis of gingiva and conjunctiva with intellectual disability 11.7
36 prp systemic amyloidosis 11.7
37 amyloidosis bronchopulmonary 11.6
38 apoa1-related familial visceral amyloidosis 11.6
39 fga-related familial visceral amyloidosis 11.6
40 lyz-related familial visceral amyloidosis 11.6
41 corneal dystrophy, gelatinous drop-like 11.6
42 pigmentary disorder, reticulate, with systemic manifestations 11.5
43 lattice corneal dystrophy type ii 11.3
44 familial mediterranean fever, ar 11.3
45 periodic fever, familial 11.2
46 macroglossia 11.1
47 light chain deposition disease 11.0
48 epidermolysis bullosa acquisita 11.0
49 hereditary cerebral amyloid angiopathy 10.9
50 gerstmann-straussler disease 10.9

Comorbidity relations with Amyloidosis via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Amyloidosis:



Diseases related to Amyloidosis

Symptoms & Phenotypes for Amyloidosis

Human phenotypes related to Amyloidosis:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 hemiparesis 32 HP:0001269
2 facial palsy 32 HP:0010628
3 inguinal hernia 32 HP:0000023
4 renal insufficiency 32 HP:0000083
5 abnormality of vision 32 HP:0000504
6 abnormality of the cardiovascular system 32 HP:0001626
7 hyperkeratosis 32 HP:0000962
8 corneal dystrophy 32 HP:0001131
9 everted lower lip vermilion 32 HP:0000232
10 nephrotic syndrome 32 HP:0000100
11 protruding ear 32 HP:0000411
12 glomerulopathy 32 HP:0100820
13 palpebral edema 32 HP:0100540
14 abnormality of the immune system 32 HP:0002715
15 aplasia/hypoplasia of the skin 32 HP:0008065
16 impaired pain sensation 32 HP:0007328
17 talipes equinovarus 32 HP:0001762
18 redundant skin 32 HP:0001582
19 generalized hyperpigmentation 32 HP:0007440
20 ureteral stenosis 32 HP:0000071
21 alopecia of scalp 32 HP:0002293
22 morphological abnormality of the gastrointestinal tract 32 HP:0012718

MGI Mouse Phenotypes related to Amyloidosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 IL31RA LYZ MEFV OSMR PRNP PSEN1
2 hematopoietic system MP:0005397 10.21 APOE APP B2M FGA GSN IAPP
3 immune system MP:0005387 10.18 LYZ MEFV OSMR PRNP PSEN1 SNCA
4 endocrine/exocrine gland MP:0005379 10.16 APOA1 APOE B2M FGA GSN LYZ
5 cardiovascular system MP:0005385 10.13 APOA1 APOE B2M CST3 FGA GSN
6 integument MP:0010771 10.1 APOA1 APOE APP B2M FGA GSN
7 liver/biliary system MP:0005370 9.8 APOA1 APOE B2M FGA LYZ MEFV
8 no phenotypic analysis MP:0003012 9.7 LYZ OSMR PRNP SNCA TTR APOE
9 reproductive system MP:0005389 9.65 APOE APP B2M CST3 FGA GSN
10 skeleton MP:0005390 9.32 APOE FGA GSN IAPP IL31RA LYZ

Drugs & Therapeutics for Amyloidosis

Drugs for Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
2
Pramlintide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 151126-32-8
3
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
4
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
5
Pravastatin Approved Phase 4 81093-37-0 54687
6
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
7
Simvastatin Approved Phase 4,Phase 2 79902-63-9 54454
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
10
Ramipril Approved Phase 4 87333-19-5 5362129
11
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
14
Donepezil Approved Phase 4,Phase 2,Phase 3 120014-06-4 3152
15
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
16
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
17
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19
Clozapine Approved Phase 4 5786-21-0 2818
20
Insulin Aspart Approved Phase 4,Phase 1 116094-23-6 16132418
21
Insulin Glargine Approved Phase 4 160337-95-1
22
Insulin Detemir Approved Phase 4 169148-63-4 5311023
23
Insulin Lispro Approved Phase 4,Phase 2,Phase 1 133107-64-9
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
26
Citalopram Approved Phase 4 59729-33-8 2771
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
28
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
29
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
30
Huperzine A Investigational Phase 4 102518-79-6
31 insulin Phase 4,Phase 3,Phase 2,Phase 1
32 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
33
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
34 Adrenergic Agents Phase 4,Phase 2
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Early Phase 1
41 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
45 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Vitamins Phase 4,Phase 3,Phase 2
47 Excitatory Amino Acid Antagonists Phase 4,Phase 3
48 Excitatory Amino Acids Phase 4,Phase 3
49 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Antidepressive Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 759)
id Name Status NCT ID Phase
1 The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease Completed NCT00046358 Phase 4
2 Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Completed NCT02681172 Phase 4
3 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4
4 Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's Completed NCT00980785 Phase 4
5 The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria Completed NCT00674596 Phase 4
6 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4
7 Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Completed NCT00303277 Phase 4
8 Continuous Subcutaneous Infusion of Pramlintide and Insulin Completed NCT00291772 Phase 4
9 Myocardial Protection of Exenatide in AMI Completed NCT01580514 Phase 4
10 A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes Completed NCT00502138 Phase 4
11 Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus Completed NCT00442767 Phase 4
12 Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes Completed NCT00212290 Phase 4
13 The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes Completed NCT00950677 Phase 4
14 Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia Completed NCT00690235 Phase 4
15 A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Completed NCT00240253 Phase 4
16 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4
17 Double Blind Atorvastatin Amlodipine Study Completed NCT00159718 Phase 4
18 Study to Determine the Digestive and Physiological Effects of an Extract From Bran in Healthy Men and Women Completed NCT01073969 Phase 4
19 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed NCT01269047 Phase 4
20 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Recruiting NCT01683825 Phase 4
21 The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis Recruiting NCT03040427 Phase 4
22 Escitalopram Effects on CSF Amyloid Beta Recruiting NCT02161458 Phase 4
23 Effects of Brain Beta-Amyloid on Postoperative Cognition Recruiting NCT01606488 Phase 4
24 Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients Recruiting NCT00842920 Phase 4
25 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
26 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Active, not recruiting NCT01841359 Phase 4
27 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4
28 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4
29 Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Not yet recruiting NCT02931136 Phase 4
30 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
31 Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL Terminated NCT01450410 Phase 4
32 Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes Withdrawn NCT00505882 Phase 4
33 Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus Unknown status NCT01137695 Phase 3
34 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
35 Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia Unknown status NCT00923715 Phase 3
36 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis Completed NCT01998503 Phase 3
37 A Trial for Systemic Light-chain (AL) Amyloidosis Completed NCT01277016 Phase 3
38 Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Completed NCT01215747 Phase 3
39 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3
40 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis Completed NCT00344526 Phase 3
41 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3
42 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3
43 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3
44 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3
45 Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain Completed NCT00857415 Phase 3
46 Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects Completed NCT01265394 Phase 3
47 PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus Completed NCT01053312 Phase 3
48 Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology Completed NCT01020838 Phase 3
49 Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels Completed NCT01165554 Phase 3
50 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3

Search NIH Clinical Center for Amyloidosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: amyloidosis

Genetic Tests for Amyloidosis

Genetic tests related to Amyloidosis:

id Genetic test Affiliating Genes
1 Amyloidosis 24

Anatomical Context for Amyloidosis

MalaCards organs/tissues related to Amyloidosis:

39
Heart, Liver, Kidney, Bone, Tongue, Spleen, Skin

Publications for Amyloidosis

Articles related to Amyloidosis:

(show top 50) (show all 2904)
id Title Authors Year
1
Marked biochemical difference in amyloid proportion between intra- and extraocular tissues in a liver-transplanted patient with hereditary ATTR amyloidosis. ( 28081655 )
2017
2
Reflectance confocal microscopy for the characterization of primary cutaneous amyloidosis: a pilot study. ( 28083882 )
2017
3
Successful treatment of lichen amyloidosis accompanied by atopic dermatitis by fractional CO2 laser. ( 28535110 )
2017
4
The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. ( 28381753 )
2017
5
Lichen amyloidosis associated with rheumatoid arthritis: unique presentation in a Bulgarian patient. ( 28076615 )
2017
6
Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes. ( 28050864 )
2017
7
Periocular Amyloidosis Manifesting as Pseudopemphigoid Treated With Mitomycin C. ( 28079687 )
2017
8
Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review. ( 28056871 )
2017
9
The M694I/M694I genotype: A genetic risk factor of AA-amyloidosis in a group of Algerian patients with familial Mediterranean fever. ( 27956278 )
2017
10
Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. ( 28049649 )
2017
11
Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation. ( 28081656 )
2017
12
Early diagnosis of systemic amyloidosis by means of a transverse carpal ligament biopsy carried out during carpal tunnel syndrome surgery. ( 28073516 )
2017
13
Coexistence of amyloidosis and Primary SjAPgren's Syndrome: An overview Amyloidosis and SjAPgren's syndrome. ( 28049394 )
2017
14
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. ( 27729322 )
2017
15
Cardiac Amyloidosis Associated With Amyloidogenic Transthyretin V122I Variant in an Elderly Japanese Woman. ( 28090011 )
2017
16
Localized amyloidosis of the stomach mimicking a superficial gastric cancer. ( 27170299 )
2016
17
Fatal recurrent dermatoneuro syndrome associated with systemic AL amyloidosis. ( 26754417 )
2016
18
Erratum to: Standardization of (99m)Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. ( 27650442 )
2016
19
Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis. ( 26760309 )
2016
20
A patient with AL amyloidosis with negative free light chain results. ( 26677890 )
2016
21
Isaacs' syndrome with overlapping myopathy as the first manifestation of AL amyloidosis. ( 27699467 )
2016
22
Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. ( 27288311 )
2016
23
Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa. ( 27791393 )
2016
24
Tracheobronchomegaly associated with laryngo-tracheal amyloidosis: First case report. ( 26791590 )
2016
25
Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. ( 26658109 )
2016
26
Hereditary Amyloidosis with Recurrent Lung Infiltrates. ( 27872470 )
2016
27
Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone. ( 27629972 )
2016
28
Bleeding manifestations in a patient with amyloidosis. ( 28049118 )
2016
29
Molecular basis of a novel renal amyloidosis due to N184K gelsolin variant. ( 27633054 )
2016
30
Tracheomalacia in a patient with tracheobronchial amyloidosis. ( 27478146 )
2016
31
Isolated primary amyloidosis of the inferior rectus muscle mimicking Graves' orbitopathy. ( 28076605 )
2016
32
Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units. ( 27292694 )
2016
33
Nodular Cutaneous Amyloidosis at the Temple. ( 27504090 )
2016
34
2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (a8 ). ( 27494229 )
2016
35
Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis. ( 27662288 )
2016
36
Nuclear imaging of cardiac amyloidosis. 'We've only just begun'. ( 27638743 )
2016
37
Rare and unusual clinicopathologic presentation of renal AL amyloidosis. ( 27186381 )
2016
38
Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. ( 26812792 )
2016
39
Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. ( 26867784 )
2016
40
Growth Hormone and Cerebral Amyloidosis. ( 27214308 )
2016
41
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. ( 27904139 )
2016
42
Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. ( 27647161 )
2016
43
Systemic AL amyloidosis associated with WaldenstrAPm macroglobulinemia: an unusual presenting complication. ( 27127826 )
2016
44
Penile ulcers complicating systemic AL amyloidosis: a case report. ( 27187183 )
2016
45
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. ( 26943606 )
2016
46
Editor's choice: Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease? ( 26908764 )
2016
47
Primary Laryngo-tracheobronchial Amyloidosis: An Unusual Cause of Hoarseness and Dyspnea. ( 27647204 )
2016
48
Mediastinal nodular AL-amyloidosis with progressive calcification. ( 27521579 )
2016
49
A Liver transplantation followed by autologous stem cell transplantation for acute liver failure caused by AL amyloidosis. Case report and review of the literature. ( 27236160 )
2016
50
Evaluation of Myocardial Strain in Patients With Amyloidosis Using Cardiac Magnetic Resonance Feature Tracking. ( 28063633 )
2016

Variations for Amyloidosis

Expression for Amyloidosis

Search GEO for disease gene expression data for Amyloidosis.

Pathways for Amyloidosis

Pathways related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 APP B2M CST3 FGA GSN IL31RA
2
Show member pathways
13.49 APOA1 APP B2M CST3 FGA GSN
3
Show member pathways
13.41 APOA1 APP B2M CST3 FGA GSN
4
Show member pathways
12.09 APOA1 APOA2 APOE TTR
5
Show member pathways
11.69 APOA1 APOE SAA1
6
Show member pathways
11.69 APOA1 APOE SAA1 SAA2 SAA4
7 11.61 APOE APP CST3 PRNP PSEN1 SNCA
8
Show member pathways
11.44 APOA1 APOA2 APOE
9 11.2 APOE APP PSEN1
10 10.75 APP CST3 PSEN1
11 10.59 APP SAA1

GO Terms for Amyloidosis

Cellular components related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.97 APOA1 APP B2M FGA PRNP PSEN1
2 neuronal cell body GO:0043025 9.93 APOE CST3 IAPP PSEN1 SNCA
3 axon GO:0030424 9.88 APP CST3 IL31RA PSEN1 SNCA
4 endoplasmic reticulum lumen GO:0005788 9.87 APOA1 APOA2 APOE APP B2M CST3
5 blood microparticle GO:0072562 9.83 APOA1 APOA2 APOE FGA GSN
6 tertiary granule lumen GO:1904724 9.73 B2M CST3 LYZ
7 rough endoplasmic reticulum GO:0005791 9.72 APP PSEN1 SNCA
8 extracellular vesicle GO:1903561 9.7 APOA1 APOE FGA
9 very-low-density lipoprotein particle GO:0034361 9.63 APOA1 APOA2 APOE
10 low-density lipoprotein particle GO:0034362 9.58 APOA1 APOE
11 spherical high-density lipoprotein particle GO:0034366 9.58 APOA1 APOA2
12 endocytic vesicle lumen GO:0071682 9.58 APOA1 APOE SAA1
13 ciliary rootlet GO:0035253 9.57 APP PSEN1
14 chylomicron GO:0042627 9.54 APOA1 APOA2 APOE
15 intermediate-density lipoprotein particle GO:0034363 9.51 APOA1 APOE
16 extracellular space GO:0005615 9.5 APOA1 APOA2 APOE APP B2M CST3
17 high-density lipoprotein particle GO:0034364 9.43 APOA1 APOA2 APOE SAA1 SAA2 SAA4
18 extracellular exosome GO:0070062 10.1 APOA1 APOA2 APOE APP B2M CST3
19 extracellular region GO:0005576 10 APOA1 APOA2 APOE APP B2M CST3

Biological processes related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 48)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.97 APOA1 APOA2 APOE APP CST3 FGA
2 positive regulation of catalytic activity GO:0043085 9.88 APOA2 APOE PSEN1
3 negative regulation of protein phosphorylation GO:0001933 9.86 PRNP PSEN1 SNCA
4 cholesterol homeostasis GO:0042632 9.85 APOA1 APOA2 APOE
5 cholesterol metabolic process GO:0008203 9.85 APOA1 APOA2 APOE APP
6 lipoprotein metabolic process GO:0042157 9.84 APOA1 APOA2 APOE
7 negative regulation of inflammatory response GO:0050728 9.84 APOA1 APOE MEFV SAA1
8 learning or memory GO:0007611 9.83 APP PRNP PSEN1
9 protein destabilization GO:0031648 9.81 GSN PRNP SNCA
10 acute-phase response GO:0006953 9.79 SAA1 SAA2 SAA4
11 positive chemotaxis GO:0050918 9.78 SAA1 SAA2 SAA4
12 retinoid metabolic process GO:0001523 9.78 APOA1 APOA2 APOE TTR
13 cholesterol efflux GO:0033344 9.73 APOA1 APOA2 APOE
14 response to oxidative stress GO:0006979 9.72 APOE APP CST3 PRNP PSEN1
15 cellular copper ion homeostasis GO:0006878 9.7 APP PRNP
16 positive regulation of receptor recycling GO:0001921 9.7 PSEN1 SNCA
17 low-density lipoprotein particle remodeling GO:0034374 9.7 APOA2 APOE
18 reverse cholesterol transport GO:0043691 9.7 APOA1 APOA2 APOE
19 supramolecular fiber organization GO:0097435 9.69 CST3 SNCA
20 cellular response to copper ion GO:0071280 9.69 PRNP SNCA
21 high-density lipoprotein particle remodeling GO:0034375 9.69 APOA1 APOA2 APOE
22 amyloid precursor protein metabolic process GO:0042982 9.68 APOE PSEN1
23 amyloid fibril formation GO:1990000 9.68 APP GSN
24 neuron projection regeneration GO:0031102 9.67 APOA1 APOE
25 cellular response to beta-amyloid GO:1904646 9.66 APP PSEN1
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 APOA1 APOA2
27 peptidyl-methionine modification GO:0018206 9.65 APOA1 APOA2
28 regulation of Cdc42 protein signal transduction GO:0032489 9.65 APOA1 APOE
29 regulation of intestinal cholesterol absorption GO:0030300 9.64 APOA1 APOA2
30 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.63 APP PSEN1
31 high-density lipoprotein particle assembly GO:0034380 9.63 APOA1 APOA2 APOE
32 negative regulation of lipase activity GO:0060192 9.62 APOA1 APOA2
33 negative regulation of long-term synaptic potentiation GO:1900272 9.62 APOE PRNP
34 phospholipid efflux GO:0033700 9.61 APOA1 APOA2 APOE
35 astrocyte activation involved in immune response GO:0002265 9.6 APP PSEN1
36 protein oxidation GO:0018158 9.59 APOA1 APOA2
37 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.58 APOA1 APOA2
38 lipoprotein biosynthetic process GO:0042158 9.58 APOA1 APOA2 APOE
39 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.57 APP PSEN1
40 chylomicron assembly GO:0034378 9.54 APOA1 APOA2 APOE
41 cellular protein metabolic process GO:0044267 9.47 APOA1 APOA2 APOE APP B2M CST3
42 positive regulation of cholesterol esterification GO:0010873 9.43 APOA1 APOA2 APOE
43 chylomicron remodeling GO:0034371 9.33 APOA1 APOA2 APOE
44 high-density lipoprotein particle clearance GO:0034384 9.13 APOA1 APOA2 APOE
45 apoptotic process GO:0006915 10.15 APP CST3 GSN IAPP PSEN1 SNCA
46 innate immune response GO:0045087 10.09 APP B2M FGA MEFV SAA1
47 neutrophil degranulation GO:0043312 10.05 B2M CST3 GSN LYZ PSEN1 TTR
48 response to drug GO:0042493 10.04 APOA1 APOA2 B2M CST3 SNCA

Molecular functions related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 cholesterol binding GO:0015485 9.65 APOA1 APOA2 APOE
2 phospholipid binding GO:0005543 9.62 APOA1 APOA2 APOE SNCA
3 chemoattractant activity GO:0042056 9.58 SAA1 SAA2 SAA4
4 tau protein binding GO:0048156 9.55 APOE SNCA
5 high-density lipoprotein particle binding GO:0008035 9.54 APOA1 APOA2
6 lipid transporter activity GO:0005319 9.54 APOA1 APOA2 APOE
7 lipase inhibitor activity GO:0055102 9.52 APOA1 APOA2
8 lipoprotein particle binding GO:0071813 9.51 APOA1 APOE
9 cuprous ion binding GO:1903136 9.49 PRNP SNCA
10 apolipoprotein receptor binding GO:0034190 9.46 APOA1 APOA2
11 beta-amyloid binding GO:0001540 9.46 APOA1 APOE CST3 PRNP
12 high-density lipoprotein particle receptor binding GO:0070653 9.43 APOA1 APOA2
13 cholesterol transporter activity GO:0017127 9.43 APOA1 APOA2 APOE
14 identical protein binding GO:0042802 9.32 APOA1 APOE APP B2M CST3 IAPP
15 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.13 APOA1 APOA2 APOE

Sources for Amyloidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....